[A17-06] Pembrolizumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 15.05.2017
Commission awarded on 10.02.2017 by the Federal Joint Committee (G-BA).
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.